BMY 21190

Drug Profile

BMY 21190

Latest Information Update: 15 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-ischaemics; Antithrombotics
  • Mechanism of Action Cyclic AMP phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary thrombosis; Thrombosis

Most Recent Events

  • 01 Sep 1998 No-Development-Reported for Coronary thrombosis in USA (Unknown route)
  • 01 Sep 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
  • 20 Feb 1995 A preclinical study has been added to the Ischaemic heart disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top